抗人胸腺马细胞免疫球蛋白(Anti-human thymocyte equine immunoglobulin(Pfizer)) - 在研适应症：再生障碍性贫血_专利_临床

概要

基本信息

药物类型

抗毒素

别名

ATGAM、アトガム

靶点-

作用方式

抑制剂

作用机制

胸腺细胞抑制剂

治疗领域

血液及淋巴系统疾病其他疾病

在研适应症

再生障碍性贫血

非在研适应症-

原研机构

Pfizer Japan, Inc.

在研机构

Pfizer Japan, Inc.

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

日本 (2023-03-27),

再生障碍性贫血

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与抗人胸腺马细胞免疫球蛋白相关的临床试验

NCT06039020

/ Active, not recruitingN/A

ATGAM INTRAVENOUS INFUSION 250mg GENERAL INVESTIGATION

The objective of this study is to confirm the safety of ATGAM in patients with moderate to severe aplastic anemia under the actual use in Japan.
The registration criteria is patients with moderate to severe aplastic anemia who receive ATGAM.
The observation period is 24 weeks (6 months) from the start of administration (Day 1). However, in cases where treatment has been completed or discontinued less than 24 weeks after the start of administration, observation is continued until completion (discontinuation) of treatment.

开始日期2024-02-21

申办/合作机构

Pfizer Inc.

NCT04862221

/ Recruiting临床2期IIT

A Phase 2b, Double-Blind, Three Arm, Randomized, Placebo Controlled Trial With Restricted Response Adaptive Randomization Testing the Efficacy and Safety of High Dose Methylprednisolone or Equine Anti-Thymocyte Globulin as Treatment for Acute Liver Failure in Pediatric Patients

TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm, randomized, controlled trial of immunosuppressive therapy for children with acute liver failure. The study will determine if suppressing inflammatory responses with either corticosteroids or equine anti-thymocyte globulin therapy improves survival for children with this rare, life-threatening condition.

开始日期2022-02-09

申办/合作机构

National Institute of Diabetes & Digestive & Kidney Diseases

[+1]

100 项与抗人胸腺马细胞免疫球蛋白相关的临床结果

登录后查看更多信息

100 项与抗人胸腺马细胞免疫球蛋白相关的转化医学

登录后查看更多信息

100 项与抗人胸腺马细胞免疫球蛋白相关的专利（医药）

登录后查看更多信息

1

项与抗人胸腺马细胞免疫球蛋白相关的文献（医药）

1990-05-01·Boletin de la Asociacion Medica de Puerto Rico

Therapy for pediatric aplastic anemia; 7 years experience at the Puerto Rico Pediatric Oncology Program.

Article

作者: Clavell, L A ; Montalvo, F W ; Casanova, R

Nine pediatric patients with aplastic or hypoplastic anemia were seen at the Pediatric Hematology-Oncology service of the University of Puerto Rico, from 1980 to first trimester of 1987. Included were eight males and one female ranging from twenty months to sixteen 8/12 years (mean 13 years). Hematomas and fever were the most common complaints. The interval since the first symptoms and the diagnosis varied from one day to one week. The peripheral cell count was abnormal in all patients; pancytopenia being the most common finding. Five of seven who received antithymocyte globulin (ATG-AM), showed improvement in their peripheral count. The median time interval from the end of ATG-AM and response was two months (range 2 weeks to 15 months).

100 项与抗人胸腺马细胞免疫球蛋白相关的药物交易

登录后查看更多信息